BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
107 results:

  • 1. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
    Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
    J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling.
    Tang Z; Yang Y; Chen W; Liang T
    Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
    Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
    Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Intraoperative pancreatoscopy can improve the detection of skip lesions during surgery for intraductal papillary mucinous neoplasia: A pilot study.
    Arnelo U; Valente R; Scandavini CM; Halimi A; Mucelli RMP; Rangelova E; Svensson J; Schulick RD; Torphy RJ; Fagerström N; Moro CF; Vujasinovic M; Matthias Löhr J; Del Chiaro M
    Pancreatology; 2023 Sep; 23(6):704-711. PubMed ID: 37336668
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by muc1 in GEM-resistant pancreatic cancer.
    Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
    Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The ema Assessment of Asciminib for the treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
    Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
    Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of pancreatic cancer Cells Through Inhibition of muc1 Expression.
    Wei D; Wang L; Liu Y; Hafley MA; Tan L; Lorenzi PL; Yang P; Zuo X; Bresalier RS
    Dig Dis Sci; 2023 Jul; 68(7):3043-3058. PubMed ID: 37071246
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular imaging Theranostics of Neuroendocrine Tumors.
    Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
    Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Altered muc1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer.
    Hong J; Guo G; Wu S; Lin S; Zhou Z; Chen S; Ye C; Li J; Lin W; Ye Y
    J Leukoc Biol; 2022 Dec; 112(6):1577-1590. PubMed ID: 36222123
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Genetic alterations shaping tumor response to anti-EGFR therapies.
    Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
    Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Targeting tumor-associated muc1 overcomes anoikis-resistance in pancreatic cancer.
    Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
    Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human muc1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo.
    Zhang L; Hou Y; Li C; Liu H; Wang Y
    Arab J Gastroenterol; 2022 Nov; 23(4):263-269. PubMed ID: 35922259
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Orthotopic and Heterotopic Murine Models of pancreatic cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
    Zhang L; Zhu J; Hou Y; Li C; Liu H
    J Cancer Res Ther; 2021 Dec; 17(7):1702-1708. PubMed ID: 35381742
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Integrated Analysis of Multi-Omics Data to Identify Prognostic Genes for pancreatic cancer.
    Jiang F; Huang X; Zhang F; Pan J; Wang J; Hu L; Chen J; Wang Y
    DNA Cell Biol; 2022 Mar; 41(3):305-318. PubMed ID: 35104421
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. muc1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.
    Luan Z; Morimoto Y; Fushimi A; Yamashita N; Suo W; Bhattacharya A; Hagiwara M; Jin C; Kufe D
    Carcinogenesis; 2022 Feb; 43(1):67-76. PubMed ID: 34657147
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    Golan T; Atias D; Stossel C; Raitses-Gurevich M
    Adv Drug Deliv Rev; 2021 Apr; 171():257-265. PubMed ID: 33617901
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review.
    Oka Y; Takano S; Kouchi Y; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Kagawa S; Hosokawa I; Mishima T; Konishi T; Kishimoto T; Ohtsuka M
    BMC Gastroenterol; 2021 Jan; 21(1):9. PubMed ID: 33407200
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
    Tsai LH; Hsu KW; Chiang CM; Yang HJ; Liu YH; Yang SF; Peng PH; Cheng WC; Wu HH
    Sci Rep; 2020 Oct; 10(1):17817. PubMed ID: 33082357
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy.
    Wang S; You L; Dai M; Zhao Y
    J Cell Mol Med; 2020 Sep; 24(18):10279-10289. PubMed ID: 32745356
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.